Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIN + Anti-PD1 in Advanced Solid Tumors
NCT06883149Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of treatment-related Adverse Events at 12 months and Immune response assessed by CD8+ T cells. Started Mar 2025; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06883149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06883149.